CTOs on the Move

AavantiBio

www.aavantibio.com

 
AavantiBio is a pre-clinical biopharmaceutical company committed to developing and commercializing novel gene transfer and gene editing therapies for the treatment of rare and ultra-rare genetic diseases. The company is rapidly building a diverse portfolio of gene transfer and gene editing therapies to target debilitating genetic diseases for which the unmet medical need is high for which there are typically no approved therapies treating the underlying disease. AavantiBio is headquartered in Cambridge, MA with additional locations in Gainesville, FL. We are looking for exceptional individuals who share our passion for developing novel therapies to treat rare diseases and advancing the ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aavantibio.com
  • 245 First Street Riverview II, 18th Floor
    Cambridge, MA USA 02142
  • Phone: n/a

Executives

Name Title Contact Details
Paul Herzich
 Chief Technology Officer Profile

Similar Companies

Advanced Biotech

Advanced Biotech is a Cobourg, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Theravance

Theravance, Inc. is focused on maximizing the potential value of the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R), with the intention of providing capital returns to stockholders. Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement with GSK, Theravance is eligible to receive the associated royalty revenues from RELVAR(R)/BREO(R) ELLIPTA(R) (fluticasone furoate/vilanterol, "FF/VI"), ANORO(R) ELLIPTA(R) (umeclidinium bromide/vilanterol, "UMEC/VI") and if approved and commercialized, VI monotherapy. Theravance is also entitled to a 15% economic interest in any future payments made by GSK under agreements entered into prior to the spin-off of Theravance Biopharma, and since assigned to Theravance Respiratory Company, LLC, relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid, and any other product or combination of products that may be discovered and developed in the future under these agreements with GSK (other than RELVAR(R)/BREO(R) ELLIPTA(R), ANORO(R) ELLIPTA(R) and VI monotherapy).

Veritas Clinical Specialties

Veritas Clinical Specialties is a Topeka, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

biomarkerinc

biomarkerinc is a Campbell, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ChemNavigator

ChemNavigator is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.